Peripherin: A Novel Early Diagnostic and Prognostic Plasmatic Biomarker in Amyotrophic Lateral Sclerosis
European Journal of Neurology · 2025
DOI: 10.1111/ene.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Alessandro Bombaci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Turin ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Turin, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Peripherins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Motor neuron diseases (MND) are heterogeneous and complex neurodegenerative disorders. Biomarkers could facilitate early diagnosis, prognosis determination, and patient stratification. Among the most studied biomarkers are neurofilaments, with peripherin (PRPH), a specific type predominantly expressed in the peripheral nervous system, gaining attention. To date, no studies have evaluated PRPH in human plasma.
Methods
Sandwich‐ELISA was used to quantify plasma peripherin from 120 MND (100 ALS, 4 PMA, 15 PLS), 73 MND‐mimics, and 38 healthy‐controls (HCs). Plasma was collected at diagnosis or some months earlier. 41 ALS were evaluated longitudinally. ALSFRSr, MRC, spirometry, genetic tests, disease progression rate (PR), blood examinations, and neuropsychological tests were performed. Statistical analyses included Kruskal–Wallis, Mann–Whitney, Cox regression, and Kaplan–Meier curves.
Results
Plasma PRPH levels differed significantly among groups ( p < 0.0001), showing higher values in MND participants than MND mimics and HCs. Moreover, PRPH levels were elevated in PLS compared with HSP patients ( p = 0.0001). Differences persisted after adjusting for age and sex. ROC curve demonstrated that PRPH discriminated MND from MND mimics (AUC = 0.85). Elevated PRPH correlated positively with ALSFRSr and lower motor neuron index, whereas inversely with disease progression rate. Higher PRPH levels at the beginning of the disease were associated with longer survival.
Discussion
Plasma PRPH is raised in MND, particularly ALS, from the earliest stages, distinguishing MND from mimics and correlating with clinical parameters and survival. This suggests PRPH may reflect an endogenous response of lower motor neuron to injury. Further multicenter studies are required to refine the diagnostic and prognostic utility of PRPH in MND.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Turin ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Turin, Italy.
- IRCSS Policlinico San Donato, San Donato, Milanese, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- SC Neurologia 1U, AOU Città Della Salute e Della Scienza di Torino, Turin, Italy.
ORCID-Profile: Alessandro Bombaci, Andrea Calvo
Zitieren
APA
Bombaci, A., De Marco, G., Casale, F., Salamone, P., Marchese, G., Fuda, G., Calvo, A., & Chiò, A. (2025). Peripherin: A Novel Early Diagnostic and Prognostic Plasmatic Biomarker in Amyotrophic Lateral Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70241
Vancouver
Bombaci A, De Marco G, Casale F, Salamone P, Marchese G, Fuda G, et al. Peripherin: A Novel Early Diagnostic and Prognostic Plasmatic Biomarker in Amyotrophic Lateral Sclerosis. European Journal of Neurology. 2025. doi:10.1111/ene.70241
BibTeX
@article{Bombaci2025,
author = {Bombaci, Alessandro and De Marco, Giovanni and Casale, Federico and Salamone, Paolina and Marchese, Giulia and Fuda, Giuseppe and Calvo, Andrea and Chiò, Adriano},
title = {Peripherin: A Novel Early Diagnostic and Prognostic Plasmatic Biomarker in Amyotrophic Lateral Sclerosis},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70241}
}
EUVIMED